P

Inventor

WU WEN-LIAN

US37 patents
⚠️ This page may combine multiple inventors who share the name “WU WEN-LIAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

SCHERING CORP

13 patents
US6664273B2Dec 16, 2003

Piperidine based MCH antagonists for treatment of obesity and CNS disorders

SCHERING CORP45 citations92
US7482360B2Jan 27, 2009

Fused tetracyclic mGluR1 antagonists as therapeutic agents

SCHERING CORP15 citations84
US7109207B2Sep 19, 2006

Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

SCHERING CORP13 citations83
US7598259B2Oct 6, 2009

mGluR1 antagonists as therapeutic agents

SCHERING CORP2 citations61
US7214691B2May 8, 2007

2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

SCHERING CORP6 citations61
US7211574B2May 1, 2007

Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders

SCHERING CORP1 citations52
US7989464B2Aug 2, 2011

mGluR1 antagonists as therapeutic agents

SCHERING CORP0 citations50
US7485648B2Feb 3, 2009

mGluR1 antagonists as therapeutic agents

SCHERING CORP1 citations50
US7767815B2Aug 3, 2010

Fused tricyclic mGluR1 antagonists as therapeutic agents

SCHERING CORP0 citations41
US7498441B2Mar 3, 2009

Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders

SCHERING CORP0 citations41
US7511146B2Mar 31, 2009

2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

SCHERING CORP0 citations38
US6903123B2Jun 7, 2005

Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1

SCHERING CORP0 citations37
US7423149B2Sep 9, 2008

Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders

SCHERING CORP0 citations36

MERCK SHARP & DOHME

11 patents
US10689401B2Jun 23, 2020

C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use

MERCK SHARP & DOHME2 citations72
US9365589B2Jun 14, 2016

C5, C6 oxacyclic-fused thiazine dioxide compounds as BACE inhibitors, compositions, and their use

MERCK SHARP & DOHME7 citations71
US11008338B2May 18, 2021

C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use

MERCK SHARP & DOHME0 citations62
US10414774B2Sep 17, 2019

Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease

MERCK SHARP & DOHME1 citations61
US11466047B2Oct 11, 2022

Cyclic di-nucleotide compounds as sting agonists

MERCK SHARP & DOHME0 citations52
US9453034B2Sep 27, 2016

C2-azaspiro iminothiazine dioxides as BACE inhibitors, compositions, and their use

MERCK SHARP & DOHME2 citations52
US11685761B2Jun 27, 2023

Cyclic di-nucleotide compounds as sting agonists

MERCK SHARP & DOHME0 citations51
US9732088B2Aug 15, 2017

C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use

MERCK SHARP & DOHME1 citations51
US9725468B2Aug 8, 2017

C5-spiro iminothiazine dioxides as BACE inhibitors, compositions, and their use

MERCK SHARP & DOHME0 citations42
US10071998B2Sep 11, 2018

Iminothiadiazine dioxides bearing an amine-linked substituent as BACE inhibitors, compositions, and their use

MERCK SHARP & DOHME0 citations41
US10414775B2Sep 17, 2019

Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease

MERCK SHARP & DOHME0 citations37

WU WEN-LIAN

6 patents

ANGEX PHARMACEUTICAL INC

3 patents

ASBEROM THEODROS

2 patents

SASIKUMAR THAVALAKULAMGARA K

1 patent

BURNETT DUANE A

1 patent